Clinical Trial

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

Study acronym: BAH242
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated December 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients suffering from resistant systemic lupus erythematosus can tolerate.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-01.
Status change: Not Yet Recruiting → Recruiting 2024-10-11
Trial Details
NCT Number NCT06350110
Lead Sponsor Essen Biotech
Conditions Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis, Systemic Sclerosis, Idiopathic Inflammatory Myopathies +1 more
Enrollment 75 participants
Start Date 2024-07-10
Primary Completion 2025-12-10 (estimated)
Study Completion 2025-12-28 (estimated)
Updated on ClinicalTrials.gov 2024-10-15